Drug Trial Radar · NCT06079879
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Dec 31, 2023
Primary completion
Jul 14, 2027
Study completion Aug 18, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Conditions
- Essential Thrombocythemia
Interventions
BomedemstatDrug
Oral Capsule
AnagrelideDrug
Oral Capsule
BusulfanDrug
Oral Tablet
Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2bDrug
Subcutaneous Solution
RuxolitinibDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Durable Clinicohematologic Response (DCHR) RateTime frame: Up to approximately 52 weeks
Locations
161 sites in 24 countries. Site status is shown where the registry gives one.
Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)
Glendale, Arizona
Los Angeles Cancer Network ( Site 3491)
Glendale, California
Stanford Cancer Institute ( Site 0107)
Stanford, California
The Lundquist Institute ( Site 3423)
Torrance, California
University of Colorado Anschutz Medical Campus ( Site 3425)
Aurora, Colorado
Tufts Medical Center ( Site 3408)
Boston, Massachusetts
University of Michigan ( Site 0008)
Ann Arbor, Michigan
Henry Ford Hospital ( Site 3413)
Detroit, Michigan
Optum Care Cancer Center ( Site 3497)
Las Vegas, Nevada
Roswell Park Cancer Institute ( Site 3421)
Buffalo, New York
Duke University Health System (DUHS) ( Site 0016)
Durham, North Carolina
Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)
Winston-Salem, North Carolina
Medical University of South Carolina-Hollings Cancer Center ( Site 3426)
Charleston, South Carolina
University of Virginia ( Site 3422)
Charlottesville, Virginia
VCU Health Adult Outpatient Pavillion ( Site 3416)
Richmond, Virginia
Hospital Universitario Austral ( Site 0104)
Pilar, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires ( Site 0105)
ABB, Buenos Aires F.D., Argentina
C.I.C.E. 9 de Julio ( Site 1001)
San Miguel de Tucumán, Tucumán Province, Argentina
Royal Prince Alfred Hospital ( Site 1100)
Camperdown, New South Wales, Australia
Liverpool Hospital-Haematology ( Site 0501)
Liverpool, New South Wales, Australia
Royal North Shore Hospital ( Site 0003)
St Leonards, New South Wales, Australia
Calvary Mater Newcastle ( Site 0505)
Waratah, New South Wales, Australia
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001)
Adelaide, South Australia, Australia
Monash Health-Haematology Research ( Site 0006)
Clayton, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502)
Melbourne, Victoria, Australia
Royal Perth Hospital-Haematology ( Site 0504)
Perth, Western Australia, Australia
ZAS Cadix ( Site 1200)
Antwerp, Belgium
The Moncton Hospital-Oncology ( Site 1500)
Moncton, New Brunswick, Canada
The First Afflilated Hospital of Bengbu Medical College ( Site 3509)
Bengbu, Anhui, China
Anhui Provincial Hospital ( Site 3513)
Hefei, Anhui, China
Peking University Third Hospital-Hematology ( Site 3502)
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital ( Site 3531)
Beijing, Beijing Municipality, China
The Second Affiliated Hospital Of Fujian Medical University ( Site 3525)
Quanzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 3515)
Xiamen, Fujian, China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511)
Guangzhou, Guangdong, China
The First Hospital of Hebei Medical University ( Site 3510)
Shijiazhuang, Hebei, China
Henan Cancer Hospital-hematology department ( Site 3504)
Zhengzhou, Henan, China
Wuhan Union Hospital ( Site 3500)
Wuhan, Hubei, China
Jiangsu Province Hospital ( Site 3507)
Nanjing, Jiangsu, China
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.